Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
Cell to Cure ApS
APS
Active
Reklamebeskyttelse
CVR 39401975
Kajerødgård 9, 3460
Birkerød
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2018 · 8 years old
14 employees
Overvåg
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Cell to Cure ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
-3M
2024
-3M
2025
EBITDA
DKK millions
0M
-4M
-8M
-11M
-15M
0M
2021
-1M
-100%
2022
-2M
-100%
2023
-9M
-350%
2024
-12M
-33%
2025
Income statement
DKK thousands
Item
2021
2022
2023
2024
2025
Gross profit
295
389
100
-2.803
-3.076
Staff expenses
-0
-1.047
-1.922
-6.385
-9.060
EBITDA
295
-658
-1.821
-9.187
-12.136
Depreciation & amort.
-0
-0
-0
-0
-367
EBIT
295
-658
-1.821
-9.187
-12.503
Net financials
-15
-14
-110
-52
-206
Profit before tax
280
-672
-1.931
-9.240
-12.709
Tax
62
-270
-398
-2.253
-2.916
Net profit
218
-402
-1.534
-6.987
-9.793
Balance sheet
DKK thousands
Item
2021
2022
2023
2024
2025
Total assets
1.014
1.487
1.871
6.080
9.578
Equity
695
-366
-1.899
3.114
-1.179
Long-term debt
62
0
1.392
0
0
Short-term debt
258
1.853
2.353
2.966
10.757
Total debt
320
1.853
3.746
2.966
10.757
Financial ratios
5-year trend
EBITDA-margin (af bruttofortjeneste)
-1213616400.0%
This company
2021
2025
Soliditetsgrad
-12.3%
This company
38.2%
Market median
-132% vs market
2021
2025
Egenkapitalforrentning
-979260400.0%
This company
18.4%
Market median
-5322067491% vs market
2021
2025
Nettoresultatgrad (af bruttofortjeneste)
-979260400.0%
This company
2021
2025
Aktivomsætning (af bruttofortjeneste)
-0.32×
This company
2021
2025
Gæld/egenkapital
9.12×
This company
0.62×
Market median
-1371% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2023-09-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2022-09-01 – 2023-08-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2021-09-01 – 2022-08-31
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2020-09-01 – 2021-08-31
View
PDF
More on Cell to Cure ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
